Mid to long-term clinical outcomes improvement through dual antiplatelet therapy after coronary artery bypass grafting: Interpretation of DACAB-FE trial
- VernacularTitle:冠状动脉旁路移植术后双联抗血小板治疗改善中远期临床预后：DACAB-FE研究解读
- Author:
Jianyu QU
1
;
Si CHEN
2
;
Zhijian WANG
3
;
Kang ZHOU
4
;
Yuan ZHAO
4
;
Ran DONG
5
;
Dongmei SHI
3
;
Nianguo DONG
2
;
Zhe ZHENG
1
Author Information
1. Department of Cardiovascular Surgey, Fuwai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China
2. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, P. R. China
3. Geriatric Cardiovascular Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, P. R. China
4. Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, P. R. China
5. Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, P. R. China
- Publication Type:Journal Article
- Keywords:
Dual antiplatelet therapy;
coronary artery bypass grafting;
medium to long-term clinical outcome
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(08):1096-1100
- CountryChina
- Language:Chinese
-
Abstract:
Coronary artery bypass grafting (CABG) is one of the most effective revascularization treatments for coronary heart disease. Secondary prevention strategies, which rely on antiplatelet and lipid-lowering drugs, are crucial after CABG to ensure the durability of revascularization treatment effects and prevent adverse cardiovascular and cerebrovascular events in the medium to long term. Previous research conducted by Professor Zhao Qiang's team from Ruijin Hospital of Shanghai Jiao Tong University, known as the DACAB study, indicated that dual antiplatelet therapy (DAPT, specifically ticagrelor+aspirin) after CABG can enhance venous graft patency. However, it remains uncertain whether DAPT can further improve the medium to long-term clinical outcomes of CABG patients. Recently, the team reported the medium to long-term follow-up results of the DACAB study, termed the DACAB-FE study, finding that DAPT administered after CABG can reduce the incidence of major cardiovascular events over five years and improve patients' medium to long-term clinical outcomes. This article will interpret the methodological highlights and significant clinical implications of the DACAB-FE study.
